Introduction
Materials and methods
Patients
Tissue microarray construction
Immunohistochemistry
Statistical analysis
Results
Immunohistochemical HMG-CoAR expression in invasive breast cancer
Correlation between HMG-CoAR and relevant clinicopathological parameters
HMG-CoAR intensity | 0 | 1 to 3 | |
---|---|---|---|
n (%) | 111 (25.0) | 333 (75.0) | p value |
Age (years)
| |||
Median | 65 | 64 | |
Range | 27 to 89 | 34 to 96 | 0.84 |
≤50 | 23 (20.7) | 51 (15.5) | |
>50 | 88 (79.3) | 279 (84.5) | 0.20 |
Tumour size (mm)
| |||
Median | 20 | 15 | |
Range | 1 to 100 | 1 to 100 | <0.001 |
≤20 mm | 57 (51.4) | 217 (65.8) | |
>20 mm | 54 (48.6) | 113 (34.2) | 0.007 |
NHG
| |||
I | 11 (9.9) | 97 (29.5) | |
II | 45 (40.5) | 133 (40.4) | |
III | 55 (49.5) | 99 (30.1) | <0.001 |
Node status
| |||
Negative | 67 (65.7) | 179 (61.3) | |
Positive | 35 (34.3) | 113 (38.7) | 0.43 |
Unknown | 9 | 41 | |
ER status
| |||
Negative | 22 (20.0) | 36 (10.9) | |
Positive | 88 (80.0) | 294 (89.1) | 0.01 |
Unknown | 1 | 3 | |
PR status
| |||
Negative | 16 (14.8) | 45 (13.8) | |
Positive | 92 (85.2) | 281 (86.2) | 0.79 |
Unknown | 3 | 7 | |
n (%) | 111 (25.0) | 333 (75.0) |
p-value
|
Endocrine therapy (tamoxifen)
| |||
No | 50 (55) | 147 (59) | |
Yes | 41 (45) | 103 (41) | |
Unknown | 20 | 83 |
0.53
|
Chemotherapy
| |||
No | 81 (89) | 240 (95) | |
Yes | 10 (11) | 12 (5) | |
Unknown | 20 | 81 |
0.04
|
HER2 IHC
| |||
0 | 77 (73.3) | 155 (48.9) | |
1 | 13 (12.4) | 89 (28.1) | |
2 | 6 (5.7) | 37 (11.7) | |
3 | 9 (8.6) | 36 (11.4) |
<0.001
|
unknown | 6 | 16 | |
HER2 IHC
| |||
0 to 2 | 96 (91) | 284 (89) | |
3 | 9 (9) | 36 (11) |
0.44
|
Unknown | 6 | 16 | |
Ki67
| |||
0 to 10% | 29 (27.6) | 122 (39.5) | |
11 to 25% | 35 (33.3) | 107 (34.6) | |
>25% | 39 (41.0) | 80 (25.9) |
0.02
|
Unknown | 8 | 24 |
HMG-CoAR is associated with an improved prognosis
Recurrence-free survival | Breast cancer-specific survival | |||
---|---|---|---|---|
RR (95%CI) |
p value
| RR (95%CI) |
p value
| |
All patients
|
Univariate
|
Univariate
| ||
HMG-CoAR negative | 1.00 | 1.00 | ||
HMG-CoAR positive | 0.57 (0.40 to 0.82) | 0.002 | 0.64 (0.91 to 1.03) | 0.07 |
Multivariate
|
Multivariate
| |||
HMG-CoAR negative | 1.00 | 1.00 | ||
HMG-CoAR positive | 0.60 (0.40 to 0.92) | 0.02 | 0.66 (0.39 to 1.11) | 0.12 |
ER positive
|
Univariate
|
Univariate
| ||
HMG-CoAR negative | 1.00 | 1.00 | ||
HMG-CoAR positive | 0.46 (0.31 to 0.69) | <0.001 | 0.59 (0.34 to 1.00) | 0.02 |
ER negative
| ||||
HMG-CoAR negative | 1.00 | 1.00 | ||
HMG-CoAR positive | 1.68 (0.70 to 4.03) | 0.25 | 2.47 (0.81 to 7.54) | 0.11 |
Term of interaction*
|
0.004*
|
0.01*
| ||
ER positive
|
Multivariate
|
Multivariate
| ||
HMG-CoAR negative | 1.00 | 1.00 | ||
HMG-CoAR positive | 0.47 (0.30 to 0.73) | 0.001 | 0.67 (0.38 to 1.17) | 0.16 |
ER negative
| ||||
HMG-CoAR negative | 1.00 | 1.00 | ||
HMG-CoAR positive | 1.45(0.35 to 5.97) | 0.61 | 2.00 (0.37 to 10.93) | 0.42 |
Term of interaction*
|
0.01*
|
0.11*
|
Correlations between HMG-CoAR and relevant clinicopathological parameters in ER-positive and ER-negative tumours
ER-positive | ER-negative | |||||
---|---|---|---|---|---|---|
HMG-CoAR intensity
| 0 | 1–3 | 0 | 1–3 | ||
n (%) | 88 (23) | 294 (77) |
p value
| 22 (38) | 36 (62) |
p value
|
Age (years)
| ||||||
Median | 66 | 65 | 57 | 59 | ||
Range | 28–89 | 35–96 | 0.43 | 27–81 | 34–90 | 0.38 |
≤50 | 15 (17) | 45 (15) | 7 (32) | 8 (27) | ||
>50 | 73 (83) | 249 (85) | 0.69 | 15 (68) | 28 (73) | 0.42 |
Tumour size
| ||||||
Median | 20 | 15 | 22 | 17 | ||
Range | 1 to 100 | 1 to 100 | <0.001 | 12 to 55 | 1 to 100 | 0.10 |
≥20 mm | 48 (55) | 147 (60) | 9 (41) | 19 (53) | ||
>20 mm | 40 (45) | 97 (40) | 0.03 | 13 (59) | 17 (47) | 0.38 |
NHG
| ||||||
I | 11 (13) | 95 (32) | 0 | 1 (3) | ||
II | 40 (45) | 126 (43) | 5 (23) | 9 (25) | ||
III | 37 (42) | 72 (25) | <0.001 | 17 (77) | 26 (72) | 0.56 |
Node status
| ||||||
Negative | 48 (59) | 167 (64) | 19 (90) | 11 (36) | ||
Positive | 33 (41) | 95 (36) | 0.47 | 2 (10) | 19 (63) | <0.001 |
Unknown | 7 | 32 | 1 | 6 | ||
Tamoxifen
| ||||||
No | 41 (55) | 133 (60) | 8 (50) | 12 (44) | ||
Yes | 33 (45) | 87 (40) | 0.45 | 8 (50) | 15 (56) | 0.73 |
Unknown | 14 | 74 | 6 | 6 | ||
Chemotherapy
| ||||||
No | 67 (91) | 214 (96) | 14 (88) | 23 (85) | ||
Yes | 7 (9) | 8 (4) | 0.05 | 2 (12) | 4 (15) | 0.84 |
Unknown | 14 | 72 | 6 | 6 | ||
HER2 IHC
| ||||||
0 | 59 (71) | 144 (51) | 17 (81) | 12 (34) | ||
1 | 13 (16) | 85 (30) | 0 | 5 (14) | ||
2 | 6 (7) | 35 (12) | 0 | 1 (3) | ||
3 | 5 (6) | 19 (7) | 0.02 | 4 (19) | 17 (49) | 0.007 |
Unknown | 5 | 11 | 1 | 1 | ||
HER2 IHC
| ||||||
0 to 2 | 78 (94) | 264 (93) | 17 (80) | 18 (51) | ||
3 | 5 (6) | 19 (7) | 0.82 | 4 (20) | 17 (49) | 0.02 |
Unknown | 5 | 11 | 1 | 1 | ||
Ki67
| ||||||
0 to 10% | 27 (32) | 116 (42) | 1 (5) | 4 (12) | ||
11 to 25% | 32 (38) | 101 (37) | 3 (15) | 7 (21) | ||
>25% | 25 (30) | 58 (21) | 0.05 | 16 (80) | 23 (68) | 0.30 |
Unknown | 4 | 19 |
2
|
1
|